A new PET scan technique using [68Ga]Ga-DOTA-Folate successfully detected ovarian cancer in a patient for the first time in humans, according to research published in the Journal of Nuclear Medicine. This case report demonstrates the imaging method can visualize cancer cells effectively, though much larger studies are needed before it becomes available for routine clinical use.
Researchers tested a new type of medical imaging scan called [68Ga]Ga-DOTA-Folate PET/CT on a patient with ovarian cancer. This scan uses a special radioactive tracer that targets cancer cells more precisely than traditional imaging methods. The technique worked in this first human patient, successfully identifying cancer tissue. While this is early-stage research based on a single patient, it suggests this new imaging approach could eventually help doctors detect ovarian cancer earlier and more accurately, potentially improving treatment outcomes.
Key Statistics
A 2026 case report published in the Journal of Nuclear Medicine documented the first-in-human use of [68Ga]Ga-DOTA-Folate PET/CT imaging in a patient with ovarian cancer, with the scan successfully identifying cancer tissue.
The experimental [68Ga]Ga-DOTA-Folate PET/CT scan demonstrated good specificity for ovarian cancer detection in the single patient studied, with the radioactive tracer accumulating in cancer areas while sparing normal tissue.
The Quick Take
- What they studied: Whether a new type of PET scan using a special tracer called [68Ga]Ga-DOTA-Folate could effectively detect ovarian cancer in a real patient
- Who participated: One patient with ovarian cancer who received the experimental imaging scan
- Key finding: The new PET/CT scan successfully identified cancer tissue in the patient, demonstrating that this imaging technique can work in humans for the first time
- What it means for you: This is very early research on a single patient. While promising, much more testing is needed before this scan becomes available for routine cancer detection. Talk to your doctor about current standard imaging options for ovarian cancer screening and diagnosis.
The Research Details
This was a case report, which is the simplest type of medical research. The researchers tested a brand-new imaging technique on one patient with ovarian cancer. The scan uses a radioactive tracer (a special dye) that attaches to cancer cells, making them visible on imaging. The tracer is called [68Ga]Ga-DOTA-Folate, and it works by targeting specific proteins that cancer cells often have on their surface. The patient received the injection and then underwent a PET/CT scan, which combines two imaging technologies to create detailed pictures of the body.
PET stands for Positron Emission Tomography, and it detects the radioactive tracer. CT stands for Computed Tomography, and it takes detailed X-ray images. Together, they show both where the tracer is located and the exact anatomy of the area. This combination helps doctors see cancer more clearly than either scan alone.
Case reports are important for introducing completely new medical techniques to the scientific community. This is the first time this specific tracer has been used in a human patient, so documenting that it works safely and effectively is a crucial first step. Before a new imaging technique can be used widely, researchers need to prove it’s safe, that it actually detects cancer, and that it provides useful information doctors can act on. This case report provides that initial proof of concept.
This is a very early-stage study with significant limitations. It involves only one patient, so we cannot draw broad conclusions. There is no comparison group, no control group, and no statistical analysis possible with a single case. The findings are promising but preliminary. Much larger studies with many more patients are needed to confirm this technique works reliably and is better than existing imaging methods. This research should be viewed as an important first step, not as definitive evidence.
What the Results Show
The [68Ga]Ga-DOTA-Folate PET/CT scan successfully detected cancer tissue in the patient with ovarian cancer. The radioactive tracer accumulated in areas where cancer was present, making the tumors visible on the imaging. This demonstrates that the tracer can reach cancer cells in humans and that the imaging technique can visualize them effectively.
The scan provided clear images that allowed doctors to see the location and extent of the cancer. The tracer appeared to have good specificity, meaning it targeted cancer cells rather than accumulating in normal, healthy tissue. This is an important characteristic because it means the scan could potentially distinguish between cancer and non-cancer areas more clearly than some existing imaging methods.
The scan appeared to be well-tolerated by the patient with no reported adverse effects from the radioactive tracer. The imaging quality was sufficient for clinical interpretation. The technique successfully combined the benefits of both PET and CT imaging in a single procedure.
Current standard imaging for ovarian cancer typically includes CT scans, MRI, and sometimes PET scans with different tracers like FDG-PET. This new tracer targets a different biological marker on cancer cells (folate receptors), which may offer advantages in detecting certain types of ovarian cancer. Previous research in laboratory and animal studies suggested this approach could work, but this is the first confirmation in a human patient.
This study has major limitations: it involves only one patient, so results cannot be generalized. There is no comparison to standard imaging techniques in the same patient. We don’t know if this tracer works equally well in all patients or all types of ovarian cancer. The long-term safety profile is unknown. We don’t know if the scan would miss any cancers or produce false positives. Much larger clinical trials are needed to establish the true value of this imaging technique.
The Bottom Line
This research is too preliminary to recommend this scan for clinical use. It represents an interesting proof-of-concept that warrants further investigation. Patients with ovarian cancer should continue using standard imaging methods recommended by their oncologists. If you have ovarian cancer, discuss imaging options with your medical team based on current evidence-based guidelines.
Ovarian cancer patients and their doctors should be aware of this emerging technology, but it is not yet ready for clinical application. Researchers in nuclear medicine and oncology should follow this development. Women at high risk for ovarian cancer should not expect this scan to be available soon for screening purposes.
This is very early research. If development continues successfully, it could take 5-10 years or more before this imaging technique might become available for clinical use, pending additional studies, regulatory approval, and validation in larger patient populations.
Frequently Asked Questions
Is there a new scan for detecting ovarian cancer?
Researchers developed a new PET scan using [68Ga]Ga-DOTA-Folate that successfully detected ovarian cancer in one patient for the first time in 2026. However, this is very early research, and the scan is not yet available for clinical use. Standard imaging methods remain the current standard of care.
How does the new folate PET scan work for cancer?
The scan uses a radioactive tracer that targets folate receptors, proteins commonly found on cancer cell surfaces. The tracer accumulates in cancer tissue, making tumors visible on imaging. This targeting approach may help distinguish cancer from normal tissue more effectively than some existing scans.
When will the new ovarian cancer imaging scan be available?
This technique is in very early stages of development. Much more research is needed, including larger clinical trials and regulatory approval. If development continues successfully, it could take 5-10 years or longer before becoming available for routine clinical use.
Is the new folate PET scan better than standard imaging?
This case report shows the scan can detect cancer, but we don’t yet know if it’s better than standard imaging like CT or conventional PET scans. Larger comparative studies are needed to determine its true advantages and disadvantages.
Can I get this new cancer scan now?
No, this imaging technique is not available for clinical use. It has only been tested in one patient. Patients with ovarian cancer should continue using standard imaging methods recommended by their oncology team.
Want to Apply This Research?
- Users should track their current imaging procedures and results as recommended by their oncology team. Document the type of scan received, date, and key findings to share with healthcare providers.
- Stay informed about emerging cancer detection technologies by discussing new research with your oncologist at regular appointments. Ask about clinical trials that might be available for new imaging techniques.
- Maintain regular follow-up appointments with your cancer care team. Continue with standard imaging protocols as recommended. Discuss any new imaging options that become available during your treatment course.
This research represents a very early-stage case report involving a single patient. It is not yet ready for clinical application. Patients with ovarian cancer should not expect this imaging technique to be available soon and should continue following imaging recommendations from their oncology team. This information is for educational purposes and should not replace professional medical advice. Always consult with your healthcare provider about appropriate screening, diagnostic, and treatment options for ovarian cancer.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.